Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3452W HIGH $95.50
Volume
654.43 K
Value Traded
96.32 K
Short % Float
2.4%
-14.16%Week
-33.07%1 Month
-73.33%3 Month
-96.07%6 Month
-99.98%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.96 M
EPS (TTM)
-0.52
P/E Ratio
-
Ent. Value
-266.68 K
Total Shares
19.35 M
Float Shares
18.59 M
Insiders
3.89%
Institutions
3.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KALA Catalyst Timeline
Dated clinical, regulatory and corporate events for KALA BIO, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for KALA BIO, Inc.
209Total events
3Upcoming
50Tier-1 (high impact)
2017 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Kala Bio and Virotek sign non-binding LOI with U.S. DNA testing platform to resell Virotek genetic testing products
▲Partnership / LicenseCorporate
Exclusive U.S. distribution and reseller agreement between Kala and Virotek for genetic testing and screening program
ophthalmologysource ↗
▲Partnership / LicenseCorporate
Kala Bio and Virotek announce LOI for exclusive U.S. distribution partnership
▼Reverse Stock SplitCorporate
Reverse stock split at 1-for-50 ratio effective May 8, 2026; trading on split-adjusted basis begins May 11, 2026
▲Other Regulator MilestoneEx-US Regulatory
President Trump signs Executive Order directing FDA to prioritize psychedelic review, DEA to reduce research restrictions, and establishing expanded patient access pathways
▲Product LaunchPost-Market
Initial commercial deployment of Bionic Intelligence Research Agent (BIRA)
◆Product LaunchPost-Market
First commercial AI product expected to ship in approximately 14 days
▲Partnership / LicenseCorporate
Red Light Holland engages Kala Bio's Researgency.ai platform to support PEX010 clinical development
▲Debt Royalty FinancingCorporate
Settlement of approximately $10.6 million debt with Oxford Finance
▼Equity OfferingCorporate
Second closing of $4.2M expected upon stockholder approval in Q1 2026
▼Equity OfferingCorporate
KALA BIO announces $10 million registered direct offering of common stock priced at $1.00 per share
▼Equity OfferingCorporate
KALA BIO enters $6M securities purchase agreement with David E. Lazar
◆Topline ReadoutKPI-012Clinical Data
Topline data expected from Phase 2b CHASE trial of KPI-012 in PCED
Persistent Corneal Epithelial Defect (PCED)source ↗
▼Topline ReadoutKPI-012Clinical Data
CHASE Phase 2b topline results: did not meet primary endpoint
persistent corneal epithelial defect (PCED)source ↗
▼Program DiscontinuationKPI-012Corporate
KALA to cease clinical development of KPI-012
persistent corneal epithelial defect (PCED)source ↗
▼Primary Endpoint MissedKPI-012Clinical Data
CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint
persistent corneal epithelial defect (PCED)source ↗
◆Oral PresentationPresentation
KALA BIO management to present at H.C. Wainwright 27th Annual Global Investment Conference
◆Oral PresentationPresentation
KALA BIO management to present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
▲Enrollment CompleteKPI-012Trial
Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in PCED
Persistent Corneal Epithelial Defect (PCED)source ↗
◆Oral PresentationKPI-012Presentation
Virtual KOL event discussing KPI-012 for PCED
persistent corneal epithelial defect (PCED)source ↗
▲Enrollment CompleteKPI-012Trial
Completion of patient enrollment in CHASE Phase 2b trial
persistent corneal epithelial defect (PCED)source ↗
◆Topline ReadoutKPI-012Clinical Data
Topline data from CHASE trial expected
persistent corneal epithelial defect (PCED)source ↗
◆Oral PresentationPresentation
KALA BIO management presentation at Jefferies Global Healthcare Conference
◆Enrollment UpdateKPI-012Trial
Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012
Persistent Corneal Epithelial Defect (PCED)source ↗
◆Topline ReadoutKPI-012Clinical Data
Topline data from Phase 2b CHASE trial of KPI-012 in PCED expected in Q2 2025
persistent corneal epithelial defect (PCED)source ↗
◆Enrollment UpdateKPI-012Trial
Continuing enrollment into 2Q25
Persistent Corneal Epithelial Defect (PCED)source ↗
◆Enrollment UpdateKPI-012Trial
Randomized 87 patients to date in Phase 2b CHASE trial
Persistent Corneal Epithelial Defect (PCED)source ↗
◆Oral PresentationPresentation
KALA BIO management to present at TD Cowen 45th Annual Health Care Conference
◆Topline ReadoutKPI-012Clinical Data
Topline data from Phase 2b CHASE trial of KPI-012 for PCED
Persistent Corneal Epithelial Defect (PCED)source ↗
▼Equity OfferingCorporate
Private placement of common stock and Series I Preferred Stock for $10.75 million gross proceeds
▲Enrollment MilestoneKPI-012Trial
Over 80% enrollment complete in CHASE trial
persistent corneal epithelial defectsource ↗
◆Oral PresentationPresentation
KALA BIO to present at Piper Sandler 36th Annual Healthcare Conference
◆Topline ReadoutKPI-012Clinical Data
Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted by year-end 2024
persistent corneal epithelial defect (PCED)source ↗
◆Enrollment UpdateKPI-012Trial
Ongoing patient enrollment in Phase 2b CHASE trial
Persistent Corneal Epithelial Defect (PCED)source ↗
▲Trial InitiationKPI-012Trial
Initiated five clinical trial sites in Argentina for CHASE trial
Persistent Corneal Epithelial Defect (PCED)source ↗
Past FDA Catalysts and PDUFA Decisions
How KALA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2019-12-31 | KPI-121 0.25% | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 95%
Micro Cap(rank 625 of 658)
Percentile Rank
KALA BIO, Inc. faces pipeline headwinds (20/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every KALA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| KPI-012 | persistent corneal epithelial defect (PCED) | Phase 2b | 2025-12-01 | did not meet the primary endpoint; failed to achieve statistical significance for key secondary efficacy endpoints; did not show any meaningful difference between either KPI-012 treatment arm and the placebo armRead More | KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. LazarRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Iwicki Mark TDirector | Sell | -154,894 103,540 held | $0.81 | 10/23/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in KALA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0 % | 1.00 M | 1.80 M | 83.14% ( 818.96 K) |
KALA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KALA ranks across every disease it competes in
Competitive Position is a premium feature
See how KALA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKALA News
-KALA
Sep 24, 2026Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Kala Bio and Virotek have signed a non-binding letter of intent with a U.S. DNA testing platform to resell Virotek's genomic testing products. This partnership aims to expand distribution beyond ophthalmology, with Kala benefiting from a profit-split structure. However, the agreement remains subject to final negotiations and does not guarantee revenue generation.
Read more →-KALA
Sep 17, 2026▲ +8.2%on this news
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
KALA BIO, Inc. has appointed Yenvy Truong to its advisory team to support business growth and explore expansion opportunities, including acquisitions. With two decades of experience in healthcare operations, Truong aims to leverage her expertise to identify suitable opportunities for KALA. The company is focused on diagnostics and AI-enhanced health services.
Read more →-KALA
Sep 3, 2026▲ +7.4%on this news
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Kala Bio and Virotek have finalized an exclusive distribution agreement for Virotek's ophthalmology genetic testing program in the U.S. This partnership, effective September 4, 2026, allows Kala to market and resell the program while achieving commercial milestones. The agreement also includes a profit-sharing structure and potential for future collaborations in other clinical areas.
Read more →-KALA
Sep 1, 2026▼ -20.9%on this newsshared move
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Kala Bio and Virotek have entered a letter of intent for an exclusive U.S. distribution partnership focused on genetic testing for ophthalmology. Kala will market Virotek's testing program, leveraging its existing relationships in the eye care community. The collaboration may expand into additional clinical areas, subject to future agreements and approvals.
Read more →-KALA
May 7, 2026▼ -27.8%on this news· ran to -46% by day 3
KALA BIO Announces Reverse Stock Split
KALA BIO, Inc. has announced a reverse stock split at a ratio of 1-for-50, effective May 8, 2026. The split is designed to reduce the total number of outstanding shares from approximately 929 million to about 18.5 million. This decision follows stockholder approval granting the Board discretion over the split. Shareholders will not need to exchange certificates as adjustments will be made automatically by brokers.
Read more →-KALA
May 7, 2026▼ -27.8%on this news· ran to -46% by day 3
KALA BIO Announces Reverse Stock Split Stock Will Begin Trading on Split-Adjusted Basis on May 11, 2026
KALA BIO, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-50, effective May 8, 2026. This action will reduce the total number of outstanding shares from approximately 929 million to about 18.6 million. The company's common stock will continue to be listed on the Nasdaq under the ticker KALA. Stockholders are advised that they will not require new certificates, as shares held via brokerage accounts will automatically adjust to the new ratio.
Read more →-KALA
Apr 21, 2026▼ -7.4%on this news· ran to -32% by day 3
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
Kala Bio has welcomed a transformative Executive Order signed by President Trump, which prioritizes the review of psychedelic compounds and reduces research restrictions. The initiative also establishes improved patient access pathways under the Right to Try Act and allocates $50 million for psychedelic therapy research. KALA is uniquely positioned to leverage these regulatory advancements through its partnership with Red Light Holland Corp., enhancing the development of psychedelic therapies supported by its AI platform, Researgency.ai. This policy shift marks a significant transition for the integration of psychedelic medicine into mainstream healthcare.
Read more →-KALA
Apr 1, 2026▼ -5.8%on this news
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Kala Bio Inc. has announced the appointment of Dr. Saeid Babaei as Senior Scientific Advisor. His role will focus on the evaluation of Kala's clinical assets using AI-enabled analytics and securing data integration. This collaboration aims to enhance the scientific and commercial value of existing assets, particularly in the MSC secretome space, which is projected to grow significantly in the coming years. The company plans a thorough review of its datasets to identify potential developments and indications for future growth.
Read more →-KALA
Mar 30, 2026KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
KALA BIO has launched the Bionic Intelligence Research Agent (BIRA), an autonomous AI solution for the biotechnology sector. This deployment marks a significant step in KALA's transformation into an AI infrastructure partner. BIRA operates within secure environments, ensuring data sovereignty and compliance with pharmaceutical standards. The platform is designed to enhance research capabilities while maintaining enterprise-grade security.
Read more →-KALA
Mar 18, 2026Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate
Red Light Holland has partnered with Kala Bio to utilize its Researgency.ai platform for the clinical development of PEX010, a botanical psilocybin drug candidate. This collaboration aims to enhance research planning and protocol optimization as PEX010 progresses through clinical trials. The drug candidate is being studied for various mental health conditions and has received authorization for clinical trials from both Health Canada and the FDA.
Read more →-KALA
Mar 11, 2026▲ +24.2%on this news
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
KALA BIO is set to launch its first commercial AI product through its Researgency.ai platform within the next 14 days. This marks a significant transition from a clinical-stage biotech to a dual-engine growth model that combines its drug pipeline with AI technology for the healthcare industry. The company aims to streamline operations in biotech and pharmaceuticals, addressing complex and time-sensitive processes. However, it faces challenges related to the efficacy of AI technologies and market competition.
Read more →-KALA
Mar 4, 2026KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
KALA BIO has launched a strategic initiative to develop an on-premises AI infrastructure platform called Researgency, aimed at serving the biotechnology industry. This platform allows biotech companies to deploy AI capabilities while retaining control of their proprietary data. KALA will initially use the platform for its own datasets before offering it to external clients. The company believes this approach addresses a significant technology adoption gap in the biotech sector.
Read more →-KALA
Jan 5, 2026KALA BIO Settles Approximately $10.6 million of Debt
KALA BIO, Inc. has completed a significant loan settlement with Oxford Finance, resolving approximately $10.6 million of debt obligations. This settlement included a $2 million payment made by KALA, which satisfied both the Settlement Agreement and the underlying Loan Agreement. The CEO highlighted that this milestone enhances the company's strategic flexibility by alleviating financial burdens, creating a more promising outlook for KALA's future. Additionally, KALA has granted stock awards to new employees as part of its ongoing growth initiatives.
Read more →-KALA
Dec 8, 2025▼ -6.9%on this news· ran to -23% by day 3
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO, Inc. has announced the successful closing of a $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The offering involved 10 million shares sold at $1.00 each, with proceeds intended for debt repayment and corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Read more →-KALA
Dec 4, 2025KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
KALA BIO, Inc. announced a registered direct offering of 10,000,000 shares of common stock priced at $1.00 per share, expected to raise approximately $10 million. The proceeds will be utilized to repay specific debts and for general corporate purposes. The offering is set to close around December 5, 2025, pending customary conditions. This initiative is conducted under SEC regulations, ensuring it adheres to legal standards.
Read more →-KALA
Dec 1, 2025▲ +37.7%on this newsshared move
KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
KALA BIO has entered a $6 million securities purchase agreement with investor David E. Lazar, who will also serve as the new CEO. This investment comes after the company's Phase 2b trial for KPI-012 failed to meet its primary endpoint. Despite this setback, KALA plans to continue evaluating its therapeutic candidates and explore strategic options for growth.
Read more →-KALA
Sep 29, 2025KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
KALA BIO announced that its CHASE Phase 2b clinical trial for KPI-012 did not meet its primary endpoint of complete healing of persistent corneal epithelial defect (PCED). The trial also failed to achieve statistical significance for secondary endpoints. As a result, KALA plans to discontinue the development of KPI-012 and explore strategic options to preserve cash.
Read more →-KALA
Sep 3, 2025KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
KALA BIO, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025. The management team will also hold one-on-one meetings with investors. KALA is focused on developing therapies for rare eye diseases and has received FDA designations for its lead product candidate, KPI-012.
Read more →-KALA
Sep 2, 2025KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
KALA BIO has appointed Todd Bazemore as President and CEO, following his interim role since February 2025. Bazemore's leadership is anticipated to guide the company through a pivotal phase as it approaches a key data readout for its KPI-012 treatment in a Phase 2b trial. The company aims to transition towards commercialization of its innovative therapies for rare eye diseases.
Read more →About KALA BIO, Inc.
Headquarters1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
BIOPHARMAWATCH ELITE PLUS
Trade the next KALA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime